PARP Inhibitor Biomarkers Market (By Product: Kits, Assays; By Services: BRCA 1&2 Testing, HRD Testing; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global PARP inhibitor biomarkers market size was estimated at around USD 0.94 billion in 2023 and it is projected to hit around USD 2.14 billion by 2033, growing at a CAGR of 8.57% from 2024 to 2033.

Key Pointers

• North America dominated the market with the largest market share of 44% in 2023.
• By Product, the kits segment held the largest revenue share of 66% in 2023.
• By Product, the assays segment is anticipated to grow at the noteworthy CAGR throughout the forecast period.
• By Services, the BRCA 1 & 2 testing segment generated the maximum market share of 44% in 2023.
• By Application, the breast cancer segment contributed the largest market share of 49% in 2023.
• By Application, the ovarian cancer segment is expected to expand at the highest CAGR of 9.35% from 2024 to 2033.

PARP Inhibitor Biomarkers Market Growth Factors

The growth of the PARP inhibitor biomarkers market is driven by an increasing adoption of precision medicine approaches has elevated the demand for biomarker-driven therapies like PARP inhibitors, as they offer targeted treatment options tailored to individual patients. Additionally, the rising incidence of cancer globally has created a pressing need for effective therapeutic interventions, with PARP inhibitors showing promise across various cancer types. Moreover, regulatory agencies' recognition of biomarkers as pivotal indicators for treatment selection and monitoring has expedited the approval process for PARP inhibitor biomarker assays, thereby facilitating market expansion. Furthermore, continuous technological advancements in genomics, proteomics, and bioinformatics have bolstered the discovery and validation of novel biomarkers, enhancing the development of more accurate and reliable companion diagnostics for PARP inhibitors. 

PARP Inhibitor Biomarkers Market Trends:

• Expanded Clinical Applications: PARP inhibitor biomarkers are increasingly being explored beyond their traditional use in BRCA-mutated cancers. Emerging research suggests their potential efficacy in non-BRCA-mutated tumors, such as prostate and pancreatic cancers, driving the expansion of clinical applications.
• Integration of Biomarker Testing in Clinical Practice: With the growing recognition of biomarkers' role in treatment decision-making, there's a trend towards the integration of PARP inhibitor biomarker testing into routine clinical practice. This shift emphasizes the importance of biomarker-driven therapies in oncology.
• Development of Next-Generation Biomarkers: Ongoing research efforts are focused on identifying and validating next-generation biomarkers that can predict response to PARP inhibitors more accurately. This includes markers of homologous recombination deficiency (HRD) beyond BRCA mutations, contributing to the refinement of patient selection criteria.
• Companion Diagnostics Development: Diagnostic companies are investing in the development of companion diagnostics to facilitate the identification of patients most likely to benefit from PARP inhibitor therapy. These assays aim to provide clinicians with actionable information to guide treatment decisions and optimize patient outcomes.
• Precision Oncology Initiatives: Precision oncology initiatives and collaborative research consortia are driving the discovery and validation of PARP inhibitor biomarkers. These efforts involve multidisciplinary collaborations between pharmaceutical companies, academic institutions, and diagnostic developers to accelerate biomarker-driven drug development and clinical implementation.
• Focus on Liquid Biopsy Approaches: Liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, are gaining traction for their potential to non-invasively detect and monitor biomarkers associated with PARP inhibitor response. This trend reflects the growing interest in minimally invasive biomarker testing methods for cancer patients.

Product Insights

The kits segment dominated the market in 2023, capturing the largest revenue share of 66%. These kits are widely utilized for testing and diagnosing conditions associated with gene mutations and alterations, particularly in diseases like breast cancer, where inherited gene mutations are prevalent. Market leaders are continuously prioritizing the development of innovative solutions to address the growing demand for effective diagnostics. For example, Myriad Genetics, Inc.'s myChoice CDx, an FDA-approved test, plays a pivotal role in identifying patients with advanced ovarian cancer exhibiting positive homologous recombination deficiency (HRD) status. HRD is detected in approximately 48% of ovarian cancer tumors, thereby driving market expansion.

Meanwhile, the assays segment is poised to witness the fastest compound annual growth rate (CAGR) throughout the forecast period. This growth is fueled by advancements in oncology diagnosis and screening technologies. A notable example is the PARP Activity Screening and Inhibitor Testing Assay (PASTA), introduced in January 2023. PASTA is specifically designed for semi-high-throughput in vitro analysis, enabling the evaluation of PARP inhibitors' selectivity within a 96-well plate setup. This assay facilitates the measurement of relative selectivity of PARP inhibitors and assesses ADP-ribosylation levels by individual PARPs under diverse conditions. It serves as a valuable tool in research and development settings, enabling exploration of the effects of PARP inhibitors on cancer cells and facilitating the development of new assays for potential clinical applications.              

Services Insights

In 2023, the BRCA 1 & 2 testing segment emerged as the market leader, commanding a revenue share of 44%. BRCA1 and BRCA2 genes are among the most frequently implicated genes associated with heightened cancer risk, particularly in breast and ovarian cancer cases. Functioning as tumor suppressor genes under normal conditions, BRCA1 and BRCA2 play a crucial role in shielding the body from certain cancers. The escalating incidence of cancers linked to altered BRCA1 and BRCA2 genes is projected to propel market expansion. According to research from the Memorial Sloan Kettering Cancer Center, individuals with BRCA1 or BRCA2 genetic mutations face elevated risks of developing breast, ovarian, pancreatic, prostate, or breast cancer.

Conversely, the HRD testing segment is poised to exhibit a substantial compound annual growth rate (CAGR) during the forecast period. HRD, or Homologous Recombination Deficiency, denotes a condition wherein a cell fails to repair DNA double-strand breaks effectively. HRD testing is primarily employed to guide treatment decisions for patients diagnosed with advanced ovarian cancer displaying positive HRD status. While it serves as a crucial tool in ovarian cancer management, HRD testing adoption remains comparatively lower than BRCA testing, owing to its specificity and its stronger association with BRCA mutations, as outlined in an NCBI article published in August 2021.

Application Insights

In 2023, breast cancer dominated the market application-wise, capturing the largest revenue share of 49%. This growth is primarily attributed to the increasing prevalence of breast cancer linked to gene alterations associated with BRCA1 or BRCA2 genetic mutations. According to a WHO article published in February 2023, projections suggest that by 2040, breast cancer will affect approximately 2.5 million individuals globally. Breast cancer stands as one of the most widespread forms of cancer among women, ranking as the primary cause of cancer-related fatalities in females across 95% of countries. Despite its widespread impact, survival rates vary significantly, with a significant number of deaths occurring in low- and middle-income countries. While high-income nations have witnessed considerable reductions in breast cancer mortality rates over recent decades, the same progress has not been achieved in low- and middle-income countries.

Meanwhile, the ovarian cancer segment is projected to exhibit the fastest compound annual growth rate (CAGR) of 9.35% during the forecast period. Ovarian cancer ranks as a prominent cause of mortality among women, with a woman's lifetime risk of developing ovarian cancer estimated to be around 1 in 87, as per an article from the American Cancer Society published in January 2024. Additionally, the likelihood of succumbing to this disease is approximately 1 in 130. Ovarian cancer poses a significant health challenge, particularly affecting older individuals, with the risk increasing with age, and the majority of diagnoses occurring in women over 60 years old. Despite advancements in treatment modalities, ovarian cancer persists as a leading cause of cancer-related deaths among women.

Regional Insights

In 2023, North America emerged as the dominant player in the PARP inhibitor biomarkers market, capturing a revenue share of 44%. This significant share can be attributed to several factors, including the escalating prevalence of cancer, advancements in genomic technologies, and the increasing expenditure on cancer treatment. According to an article from the American Cancer Society, projections for 2022 indicate approximately 1.9 million new cancer cases diagnosed and an estimated 609,360 cancer-related deaths in the U.S. alone.

Meanwhile, the PARP inhibitor biomarkers market in the Asia Pacific region is poised to witness substantial growth during the forecast period. This growth is primarily driven by the presence of major market players and local entities such as Illumina, Inc., QIAGEN, and Thermo Fisher Scientific, Inc. Additionally, the region's growth can be attributed to the escalating investments in PARP inhibitor biomarkers technologies, a rise in per capita income leading to increased adoption of diagnostic and therapeutic products, and government initiatives aimed at enhancing healthcare infrastructure. Furthermore, the increasing adoption of devices equipped with advanced features in emerging countries like China, Japan, and India is expected to propel market growth in the region.

PARP Inhibitor Biomarkers Market Key Companies

• Myriad Genetics, Inc.
• Ambry Genetics
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• CENTOGENE N.V.
• Amoy Diagnostics Co., Ltd.
• Invitae Corporation
• NeoGenomics Laboratories.
• QIAGEN
• Agilent Technologies, Inc.

Recent Developments

• In February 2024, Myriad Genetics, Inc., a company specializing in genetic testing and precision medicine, finalized the acquisition of select assets from Intermountain Health's Intermountain Precision Genomics (IPG) laboratory business. The acquisition encompasses Precision Oncology Testing, Precision Fluid Testing, and its CLIA-certified laboratory located in St. George, Utah.
• In January 2023, CRISPR technology played a pivotal role in uncovering new markers for resistance to PARP inhibitors in prostate cancer. Scientists utilized genome-wide CRISPR knockout screens to investigate how various genetic mutations affect the effectiveness of PARP inhibitors. A notable finding from these studies is the identification of MMS22L, a gene whose deletion significantly enhances sensitivity to PARP inhibitors.

PARP Inhibitor Biomarkers Market Segmentations:

By Product

• Kits
• Assays

By Services

• BRCA 1 & 2 Testing
• HRD Testing
• HRR Testing
• Others

By Application

• Breast Cancer
• Ovarian Cancer
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa